United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,232 shares of the business’s stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $132.94, for a total value of $163,782.08. Following the transaction, the chief executive officer now directly owns 1,372 shares of the company’s stock, valued at $182,393.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.04% on Monday, reaching $130.89. The company had a trading volume of 151,192 shares. United Therapeutics Corp. has a 12 month low of $97.52 and a 12 month high of $164.04. The stock has a 50 day moving average price of $120.41 and a 200-day moving average price of $117.31. The company has a market capitalization of $5.55 billion, a price-to-earnings ratio of 8.86 and a beta of 1.39.

United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, October 27th. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $3.38 by $0.98. United Therapeutics Corp. had a return on equity of 41.78% and a net margin of 44.40%. The firm earned $408.20 million during the quarter, compared to analyst estimates of $400.58 million. During the same quarter last year, the firm earned $3.55 EPS. United Therapeutics Corp.’s quarterly revenue was up 5.7% on a year-over-year basis. Analysts forecast that United Therapeutics Corp. will post $16.29 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for United Therapeutics Corp. (NASDAQ:UTHR)

Large investors have recently modified their holdings of the stock. Scopia Capital Management LP raised its stake in shares of United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock worth $470,154,000 after buying an additional 1,370,698 shares during the period. Vanguard Group Inc. raised its stake in shares of United Therapeutics Corp. by 1.9% in the second quarter. Vanguard Group Inc. now owns 3,632,002 shares of the biotechnology company’s stock worth $384,702,000 after buying an additional 67,618 shares during the period. BlackRock Fund Advisors raised its stake in shares of United Therapeutics Corp. by 2.5% in the third quarter. BlackRock Fund Advisors now owns 2,273,416 shares of the biotechnology company’s stock worth $268,445,000 after buying an additional 55,447 shares during the period. AJO LP raised its stake in shares of United Therapeutics Corp. by 13.8% in the second quarter. AJO LP now owns 2,141,541 shares of the biotechnology company’s stock worth $226,832,000 after buying an additional 258,931 shares during the period. Finally, State Street Corp raised its stake in shares of United Therapeutics Corp. by 6.6% in the second quarter. State Street Corp now owns 1,968,065 shares of the biotechnology company’s stock worth $208,461,000 after buying an additional 121,355 shares during the period.

Several research firms recently weighed in on UTHR. Argus restated a “hold” rating on shares of United Therapeutics Corp. in a research note on Tuesday, August 23rd. Cowen and Company restated a “buy” rating and set a $144.00 target price on shares of United Therapeutics Corp. in a research note on Friday, September 23rd. Zacks Investment Research upgraded United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $137.00 target price for the company in a research note on Wednesday, September 28th. JPMorgan Chase & Co. decreased their target price on United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a research note on Friday, July 29th. Finally, Jefferies Group restated a “hold” rating and set a $120.00 target price on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. United Therapeutics Corp. presently has a consensus rating of “Hold” and a consensus target price of $137.17.

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.